constipation-type irritable bowel syndrome
Conditions
Interventions
Experimental group:Lenalopeptides
Sponsors
Tongliang Hospital, the First Affiliated Hospital of Chongqing Medical University (Chongqing Tongliang District People's Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Diagnosed as IBS-C according to Rome IV diagnostic criteria; 3. Colonoscopy has been performed in the past 2 years to exclude intestinal organic lesions (tumor, inflammatory lesions, etc.); 4. Voluntarily accept the research plan, accept the review and follow-up on time, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients, or patients planning to have children during the study period; 2. Suffering from organic diseases that may cause constipation: such as metabolic diseases (diabetes, hypothyroidism, parathyroid disease, etc.), neurogenic diseases (Parkinson's, brain tumor, multiple sclerosis, etc.), primary colon diseases (intestinal tumors, intestinal inflammation, rectal and anal lesions, etc.); 3. Drug-induced constipation: mainly includes constipation induced by anticholinergic drugs, opioids, calcium antagonists, antidepressants, antihistamines, antispasmodics, anticonvulsants, etc.; 4. Suffering from diseases that affect the development or results of the trial: such as mental illness, gastrointestinal bleeding, intestinal obstruction, severe cardiopulmonary disease, digestive system tumors or history of gastrointestinal surgery, etc.; 5. Those who are allergic to the drugs used in this study; 6. Those who have taken drugs that affect intestinal function in the past 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| abdominal pain score;number of total voluntary defecation per week; | — |
Secondary
| Measure | Time frame |
|---|---|
| symptoms indicators;irritable bowel syndrome symptom severity score;evaluation scale based on the reported clinical outcomes of patients with chronic gastrointestinal disease;hospital anxiety and depression scale;untoward effect; | — |
Countries
China
Contacts
Public ContactZeng Guli
Tongliang Hospital, the First Affiliated Hospital of Chongqing Medical University (Chongqing Tongliang District People's Hospital)
Outcome results
None listed